Isogenica
Isogenica develops LlamdA® VHH: highly versatile small format antibodies which we use to construct next generation biotherapeutics for the treatment of cancer, inflammation and other serious diseases.
LlamdA® VHH can be assembled to create bispecific and multi-specific biotherapeutics, or used to achieve targeted drug delivery as components of ADCs and cell and gene therapies including CAR-Ts.
Isogenica’s partnerships with global biopharmaceutical companies have resulted in a deep pipeline including two clinical Phase assets and partnered pre-clinical and discovery programs.
Register for our upcoming webinar here: https://www.workcast.com/register?cpak=4194507468008465
David Mead
Director of Business Development
Mandeep Sehmi
Associate Director Marketing, Business Development
